ERBB2 and breast carcinoma: Therefore, we conceived to combine our self-synthesized TTRE with trastuzumab to construct a new targeted near-infrared fluorescence nanoprobe that would target HER2-positive breast cancer and, therefore, improve traditional photodynamic therapy, which lacks tumor targeting shortcomings.